

# CURRICULUM VITÆ

## Personal Information :

*Name:* **Olav LM Bijvoet**  
*Title:* MD PhD Professor of Medicine  
*Status:* Married (1961) Françoise Dessain  
*Children:* Anita (1962) Katinka (1963) Dominique(1965) Patrick (1966) Danielle (1968)

## Academic Record :

<i>Institutions:</i>	<i>Dates:</i>	<i>Degree:</i>
University of Amsterdam	1946 - 1953	MD
University of Amsterdam	1953 - 1955	GP
Royal Dutch Navy	1955 - 1958	Tropical Medicine
University of Amsterdam	1958 - 1959	Pharmacology
University of Nijmegen	1959 - 1963	Internal Medicine
	1967	PhD.
	1968	Lecturer
	1970	Assistant Professor
University of Leiden	1972	Full Professor

## Professional Experience :

<i>Positions:</i>	<i>Date:</i>
Physician HM Hydrographer: 'Luymes'	1955 - 1956
Head Hospital Fak Fak (New Guinea)	1956 - 1958
Assistant Pharmacology	1958 - 1959
Chef de Clinique, later Head Outpatient Clinic, Dept of Internal Medicine, University Hospital Nijmegen	1968 - 1972
Head Clinical Investigation Unit; University hospital Leiden	1972 - 1989
<i>Retired:</i>	1989

## Professional Societies :

Dutch Society for Clinical Investigation, Dutch Society for Calcium Metabolism and Bone, Belgian Bone Club, European Society for Calcium Metabolism, Bone and Tooth Society, American Society for Bone and Mineral Research, International Society for Calcium Regulating Hormones.

## Offices held :

Offices in Europ Calc Tiss Society, ICCRH and several Dutch Societies.  
Editor: Bone and Mineral & Neth J Int Med;  
Editorial Board: Mineral Metabolism, Europ J Clin Invest, Bone, Calc Tiss Res.

## Social Initiatives and Orientation :

- Co-Founder ALMA (Academische Leken Missie Actie - Medical Mission in third world countries; 1947-1967);
- Co-Founder Dutch Society for Calcium Metabolism and Bone: • Initiator, and first president Osteoporosis Panel of the Dutch Health Council.
- Developed Metabolic Unit for combined and multidisciplinary, clinical and physiological investigations of disorders of calcium metabolism guided by patient- rather than protocol- oriented methodologies.
- Introduced calcitonin, aminobisphosphonates in clinical pharmacology, and • first efficacious treatment of op to then untreatable Paget's disease of bone, • and numerous other clinical approaches.
- Initiator of Platform Vlieghinder Regio Castricum, PVRC (2003; aircraft noise and environment).

## Awards :

Honorary Member ASBMR – ISBM (American & International Society for Bone & Mineral Research)  
Honorary Member Dutch Paget's Society  
The First Annual John B Johnson Award (1988) of the Paget Foundation (Unites States)  
Member Order of Oranje-Nassau (2007).

## Scientific Record:

### Summary:

- 1963 - 1969 **Designed Method for Assessment of Renal Phosphate Transport (TmP/GFR)**
- 1967 – 1974 **Achieved Effective Treatment of Paget's Disease of Bone through Inhibitory Actions of Calcitonin and Bisphosphonates on the Modulation of Cellular Interactions in the Bone Ecosystem. Clinical and Preclinical studies**
- 1978 – 1993 **Introduction of Aminobisphosphonates. Pioneered Bisphosphonates in Paget's disease, Hypercalcemia, Metastatic Breast Cancer, Gaucher's disease, Multiple Myeloma, Juvenile Osteoporosis and Osteoporosis of Old Age**
- 1983 **Described Growth Kinetics of Calcium Oxalate Monohydrate Crystals**
- 1986 **Defined Relations between Signs and Symptoms in Paget's disease of Bone**
- 1987 **Differentiated Roles of bone and kidney in kinetics of tumor-induced hypercalcemia during treatment with bisphosphonate and sodium chloride**

### Details and Publications:

Clinical Assessment of Renal Phosphate Transport; TmP/GFR; Bone Disease; Development, Mechanism of Action and Clinical Applications of Bisphosphonates, especially the introduction of APD the first of the now widely used, efficacious Amino-Bisphosphonates; Pathophysiology of Paget's Disease of Bone; Treatment of Paget's Disease with Calcitonin and with Bisphosphonates Pathophysiology and Treatment of Hypercalcaemia of Malignancy with Bisphosphonate; Management of Metastatic Bone Disease in Breast Cancer; Kidney Stones; Development of Method to Measure separately Crystal Solubility, Growth, and Agglomeration in Artificial Fluids and in Urine. Causes and Diagnosis of Calcium Oxalate Stone Disease. Numerous Peer-reviewed publications and citations in international literature.

#### 1. Bloedspiegel, Tubulair maximum en Uitscheiding van Fosfaat.

Bijvoet Olav LM

*PhD, Catholic University Nijmegen (Dessain H, Mechelen, Eds) 1967 May:1-169. Dutch.*

#### 2. The renal phosphate threshold: its evaluation and application in different clinical conditions.

Bijvoet OL, Jansen AP, Prenen H, Majoor CL.

*Water and Electrolyte Metabolism II 1963 (de Graeff J, Leynse B Eds) Elsevier A'dam 1964.*

#### 3. The Renal Tubular Reabsorption of Phosphate in Thyrotoxicosis.

Bijvoet OL, Majoor CL.

*Clin Chim Acta. 1965 Feb;11:181-3.*

#### 4. Osteoporosis and old age.

Bijvoet OL.

*Folia Med Neerl. 1966 Feb;9(1);21-9. Dutch.*

#### 5. Thyrocalcitonin in Paget's disease.

Bijvoet OL, Jansen AP.

*Lancet 1967;ii:472.*

#### 6 Calcitonin, its effect as measured in Paget's disease.

Bijvoet OL, van der Sluys Veer J, Jansen AP.

*Calcif Tissue Res. 1968:Suppl:22.*

#### 7. Effects of calcitonin on patients with Paget's disease, thyrotoxicosis, or hypercalcaemia.

Bijvoet OL, van der Sluys Veer J, Jansen AP.

*Lancet. 1968 Apr 27;1(7548):876-81.*

#### 8. Calcitonin in hypercalcaemia.

Haas HG, Dambacher M, Bijvoet OL, van der Sluys Veer J, Jansen AP.

*Lancet. 1968 Jul 29;2(7561):217-8.*

#### 9. The homeostasis of plasma calcium and phosphate.

Bijvoet OL, van der Sluys Veer J.

*Folia Med. Neerl. 1968;11(5): 161-78. Review.*

**10. Relation of plasma phosphate concentration to renal tubular reabsorption of phosphate.**

Bijvoet OL.

*Clin Sci.* 1969 Aug;37(1):23-36

**11. The assessment of phosphate reabsorption.**

Bijvoet OL, Morgan DB, Fourman P.

*Clin Chim Acta*, 1969 Oct;26(1):15-24,

**12. Relationship between alkaline phosphatase and inorganic pyrophosphatase in young hamster-molars.**

Wöltgens JH, Bonting SL, Bijvoet OL.

*Calcif Tissue Res.* 1970;Suppl:39.

**13. Effect of long-term porcine calcitonin administration in Paget's disease or osteoporosis.**

van der Sluys-Veer J, Bijvoet OL, Smeenk D.

*Calcif Tissue Res.* 1970;Suppl:88. N

**14. Relationship of inorganic pyrophosphatase and alkaline phosphatase activities in hamster molars.**

Wöltgens JH, Bonting SL, Bijvoet OL.

*Calcif Tissue Res.* 1970;5(4):333-43.

**15. Plasma phosphate and tubular reabsorption of phosphate**

Bijvoet OL, Morgan DB,

*Lancet.* 1970 Jun 20;760(1):1345-6.

**16. Relationship between alkaline phosphatase, inorganic pyrophosphatase and L-ascorbic acid incalifying hamster-molars.**

Wöltgens JH, Bonting SL, Bijvoet OL

*Clin Odhop Relat Res.* 1971;78:296-301.

**17 Influence of sodium ethane-1-hydroxy-1,1-diphosphonate and Mg 2+ on the inorganic pyrophosphatase in calcifying hamster-molars.**

Wöltgens JH, Bonting SL, Bijvoet OL.

*Isr J Med Sci.* 1971 Mar;7(3):406.

**18. The effect of phosphate on fracture healing in rabbits.**

Nollen A, Bijvoet OL.

*Isr J Med Sci.* 1971 Mar;7(3):508-9.

**19. Natriuretic effect of calcitonin in man.**

Bijvoet OL, van der Sluys Veer J, de Vries HR, van Koppen AT.

*N Engl J Med.* 1971 Apr 1;284(13):681-8.

**20. The tubular reabsorption of phosphate in man.**

Bijvoet OL, Morgan DB.

*Phosphate et Métabol. pohsphocalcique (Hioco DJ Ed) l'Expansion Scientif. Francaise, Paris* 1971:153-80,

**21. Renal phosphate excretion in man.**

Bijvoet OL

*Folia Med Neerl.* 1972;15(2):84-9.

**22. Inorganic pyrophosphatase in mineralizing hamster molars. 3. Influence of diphosphonates.**

Wöltgens JH, Bonting SL, Bijvoet OL

*Calcif Tissue Res.* 1973;13(2):151-7.

**23. Effect of a diphosphonate on para-articular ossification after total hip replacement,**

Bijvoet OL, Nollen AJ, Slooff TJ, Feith R.

*Acta Orthop Scand.* 1974;45(6):926-34

**24. The use of a diphosphonate in para-articular ossifications after total hip replacement. A clinical study.**

Slooff TJ, Feith R, Bijvoet OL, Nollen AJ.

*Acta Orthop Belg.* 1974;40(5-6):820-8.

**25. Results of prolonged treatment of Paget's disease of bone with disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP).**

De Vries HR, Bijvoet

*Neth J Med.* 1974;17(6):281-98.

**26. Kidney-mediated effects of parathyroid hormone on extracellular homoeostasis of calcium, phosphate and acid-base balance in man.**

Froeling PG, Bijvoet OL.

*Neth J Med.* 1974;17(4-5)174-83.

**27. The Zollinger-Ellison syndrome. Observations on eight Patients.**

Lamers CB, Berretty PJ, Bijvoet OL, Joosten HJ, Lubbers EJ, Muller H, Nadorp JH, Nielander DO, Penn W, Prenen H, Schillings PH, Termote UA, Van Tongeren JR  
*Neth J Med.* 1974;17(3):94-107.

**28. Letter: Plasma-phosphate in Paget's disease.**

Bijvoet OL, de Vries HR.  
*Lancet.* 1974 Jun 22;1(7869):1283-4.

**29. The treatment of Paget's disease with calcitonin.**

Hosking DJ, Bijvoet OL.  
*Neth J Med.* 1975;18(2):53-7.

**30. Proceedings: Treatment of Paget's disease of bone with disodium ethane-1-hydroxy-1,1-diphosphonate.**

de Vries HR, Bijvoet OL, Froeling PG.  
*Endocrinol.* 1975 Mar;64(3):51P.

**31. Nomogram for derivation of renal threshold phosphate concentration.**

Walton RJ, Bijvoet OL  
*Lancet.* 1975 Aug 16;2(7929):309-10.

**32. The importance of the kidneys in phosphate homeostasis.**

Bijvoet OL  
*Phosphate Metabolism.* (Avioli L, Bordier P, et al Eds) Nouvellev.Imprimeri. Fournié, Paris 1976:421-74.

**33. Evaluation of scintigraphic and roentgenologic studies in Paget's disease under treatment.**

Vellenga CJ, Pauwels EK, Bijvoet OL, Hosking DJ.  
*Radiol Clin (Basel).* 1976;45(2-4)292-301.

**34. Paget's bone disease treated with diphosphonate and calcitonin.**

Hosking DJ, Bijvoet OL, van Aken J, Will D.  
*Lancet.* 1976 Mar 20;1(7960):615-7.

**35. Letter: Diphosphonate and calcitonin in Paget's disease.**

Hosking DJ, Bijvoet OL.  
*Lancet.* 1976 May 1;1(7966):970.

**36. Combined diphosphonate and calcitonin therapy for Paget's disease of bone.**

Hosking DJ, Bijvoet OL.  
*Calcif Tissue Res.* 1976 Aug;21 Suppl:321-6.

**37. Phylogeny of renal phosphate transport in the vertebrates.**

Bijvoet OL, Reitsma PH.  
*Adv Exp Med Biol.* 1977;81:41-53. Review.

**38. Kidney Function in Calcium and Phosphate Metabolism.**

Bijvoet OL.  
*Metabolic Bone Disease* ((Avioli LV, Krane SM Eds) Academic Press, Inc. 1977: 49-140.

**39. Calcitonin or EHDP in Paget's disease?**

Bijvoet OL, Hosking DJ, Van Aken J, Will EJ.  
*Calcif Tissue Res.* 1977 May;22 Suppl:494.

**40. A simple slide-rule method for the assessment of renal tubular reabsorption of phosphate in man.**

Walton RJ, Bijvoet OL.  
*Clin Chim Acta.* 1977 Dec 15;81(3)273-6.

**41. A new diphosphonate: dissociation between effects on cells and mineral in rats and a preliminary trial in Paget's disease.**

Lemkes HH, Reitsma PH, Frijlink W, Verlinden-Ooms H, Bijvoet OL.  
*Adv Exp Med Biol.* 1978;103:459-69.

**42. Iliac bone marrow trephine biopsy : some remarks on the technique.**

te Velde J, den Ottolander GJ, Haak HL, van 't Veer M, Hartgerink-Groeneveld CA, Spaander PJ, de Koning H, Bijvoet OL, Schicht IM.  
*Neth J Med.* 1978;21(5)221-7.

**43. The eosinophilic fibrohistiocytic lesion of the bone marrow. A mastocellular lesion in bone disease.**

te Velde J, Vismans FJ, Leenheers-Binnendijk L, Vos CJ, Smeenk D, Bijvoet OL.  
*Virchows Arch A Pathol Anat Histol.* 1978 Apr 17;377(4):277-85.

**44. Pyridoxine therapy of adult primary oxalosis.**

Will EJ, Bijvoet OL.

*Proc Eur Dial Transplant Assoc.* 1979;16:727-8.

**45. Treatment of Paget's disease with 3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)**

Frijlink WB, Bijvoet OL, te Velde J, Heynen G.

*Lancet.* 1979 Apr 14;1(8120):799-803.

**46. Inhibition of osteolytic bone lesions by 3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD).**

van Breukelen FJ, Bijvoet OL, van Oosterom AT.

*Lancet.* 1979 Apr 14;1(8120)303-5.

**47. Primary oxalosis: clinical and biochemical response to high dose pyridoxine therapy.**

Will EJ, Bijvoet OL

*Metabolism.* 1979 May;28(5):542-8

**48. Idiopathic juvenile osteoporosis.**

Vismans FJ, Bijvoet OL, Peters AC, Bots GT.

*Ned Tijdschr Geneeskcl.* 1979 Sep 1;123(35):1508-12. Dutch.

**49. Formation of antibodies to synthetic human calcitonin during treatment of Paget's disease.**

Dietrich FM, Fischer JA, Bijvoet OL.

*Acta Endocrinol (Copenh).* 1979 Nov;92(3):468-76.

**50. Kinetic studies of bone and mineral metabolism during treatment with 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) in rats.**

Reitsma PH, Bijvoet OL, Verlinden-Ooms H, van der Wee-Pals U.

*Calcif Tissue Int.* 1980;32(2)145-57.

**51. Pharmacology of disodium (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate.**

Reitsma PH, Bijvoet OL, Frijlink WB, Vismans FJ, van Breukelen

*Adv Exp Med Biol.* 1980;128:219-27.

**52. Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial.**

Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM,

Renier JC, Slovik D, Vismans FJ, Potts JT Jr.

*Br Med J.* 1980 Jun 7;280(6228):1340-4.

**53. Bisphosphonates and Paget's disease.**

Bijvoet OL, Reitsma PH, Frijlink WB.

*Lancet.* 1980 Jun 28;1(8183):1416-7.

**54. Dichloromethylene diphosphonate and calcium and phosphate metabolism.**

Reitsma PH, Frijlink WB, Bijvoet OL.

*N Engl J Med.* 1980 Jul 17;303(3)162-3.

**55. APD in Paget's disease of bone. Role of the mononuclear phagocyte system?**

Bijvoet OL, Frijlink WB, Jie K, van der Linden H, Meijer CJ, Mulder H, van Paassen HC, Reitsma PH, te

Velde, J, de Vries E, van der Wey JP.

*Arthritis Rheum.* 1980 Oct;23(10):1193-204.

**56. Measurement of renal handling of phosphate.**

Bijvoet OL.

*Renal Handling of Phosphate (Massry SG, Fleisch H. Eds) Plenum Med Book Cy. NY, 1980:1-37.*

**57. Scintigraphic aspects of the recurrence of treated Paget's disease of bone.**

Vellenga CJ, Pauwels EK, Bijvoet OL, Frijlink WB.

*Nucl Med.* 1981 Jun;22(6):510-7.

**58. Hypercalcaemia due to malignancy. Role of the kidney and treatment.**

Sleeboom HP, Bijvoet OL.

*Contrib Nephrol.* 1982;33:178-96.

**59. Bone scintigraphy in Paget's disease treated with combined calcitonin and diphosphonate (EHDP).**

Vellenga CJ, Pauwels EK, Bijvoet OL, Hosking DJ, Frijlink WB.

*Metab Bone Dis Relat Res.* 1982;4(2):103-11.

**60. Clinical and biological effects of low doses of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in Paget's disease of bone**

Heynen G, Delwaide P, Bijvoet OL, Franchimont P.  
*Eur J Clin Invest.* 1982 Feb;12(1):29-35.

**61. Regulation of calcium absorption by 1,25-dihydroxy-vitamin D--studies of the effects of a bisphosphonate treatment.**

Adami S, Frijlink WB, Bijvoet OL, O'Riordan JL, Clemens TL, Papapoulos SE.  
*Calcif Tissue Int.* 1982 Jul;34(4):317-20.

**62. Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium.**

van Breukelen FJ, Bijvoet OL, Frijlink WB, Sleeboom HP, Mulder H, van Oosterom AT.  
*Calcif Tissue Int.* 1982 Jul;34(4):321-7.

**63. In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation.**

de Vries E, van der Weij JP, van der Veen CJ, van Paassen HC, Jager MJ, Sleeboom HP, Bijvoet OL, Cats A.  
*Immunology.* 1982 Sep;47(1):157-63

**64. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodiumdichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.**

Reitsma PH, Teitelbaum SL, Bijvoet OL, Kahn AJ.  
*J Clin Invest.* 1982 Nov;70(5):927-33.

**65. Familial benign hypercalcaemia. Study of a large family.**

Menko FH, Bijvoet OL, Fronen JL, Sandler LM, Adami S, O'Riordan JL, Schopman W, Heynen G.  
*Q J Med.* 1983 Spring;52(206):120-40.

**66. Dietary recommendations to patients with urinary tract calculi.**

Lycklama a Nijeholt AA, Steenhoff-Bosma CL, Blomen LJ, Bijvoet OL.  
*Ned Tijdschr Geneesk.* 1983 Mar 5;127(10):416-20. Dutch.

**67. Apposition and resorption of bone during oral treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD)**

Reitsma PH, Bijvoet OL, Potokar M, van der Wee-Pals LJ, van Wijk-van Lennep MM.  
*Calcif Tissue Int.* 1983 May;35(3):357-61.

**68. Comparison of intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate and volume repletion in tumour induced hypercalcaemia.,**

Sleeboom HP, Bijvoet OL, van Oosterom AT, Gleed JH, O'Riordan JL.  
*Lancet.* 1983 Jul 30;2(8344)23943.

**69. Palliative pamidronate treatment in patients with bone metastases from breast cancer.**

Van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL. Et al.  
*J Clin Oncol* 1993; 11: 491-498.

**70. Growth kinetics of calcium oxalate monohydrate: I Method and validation.**

Will EJ, Bijvoet OL, Blomen LJ, van der Linden H.  
*J Crystal Growth.* 1983 Nov;64(2):297-305.

**71. Growth kinetics of calcium oxalate monohydrate: II The variation of seed concentration.**

Blomen LJ, Will EJ, Bijvoet OL, van der Linden H.  
*J Crystal Growth.* 1983 Nov;64(2):306-315.

**72. Growth kinetics of calcium oxalate monohydrate: III Variation of solution composition.**

Bijvoet OL, Blomen LJ, Will EJ, van der Linden H.  
*J Crystal Growth.* 1983 Nov;64(2):316-325.

**73. Bisphosphonates modulate the precursor-cells of osteoclasts.**

Boonekamp PN, Bijvoet OL.  
*Endocr Contr of Calcium Metab* 1984 Elsevier Sci Publ NV;Vol 8A(1983 Oct16):398

**74. The assessment of renal calcium reabsorption.**

Bijvoet OL, Harinck HI.  
*Adv Exp Med Biol.* 1984;178:111-26.

**75. Comparison between visual assessment and quantitative measurement of radioactivity on the bone scintigram in Paget's disease of bone.**

Vellenga CJ, Pauwels EK, Bijvoet OL.  
*Eur J Nucl Med.* 1984;9(12):533-7,

**76. Familial benign hypercalcaemia FBH: McK. No. 14598 1983: linkage studies in a large Dutch family.**

Menko FH, Bijvoet OL, Meera Khan P, Nijenhuis LE, von Loghem E, Schreuder I, Bernini LF, Pronk JO, Madan K, Went LN.

*Hum Genet.* 1984;67(4):452-4.

**77. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate.**

Harinck HI, Bijvoet OL, van der Meer JW, Jones B, Onvlee GJ.

*Lancet.* 1984 Sep 12(8401):513.

**78. Untreated Paget disease of bone studied by scintigraphy.**

53. Vellenga CJ, Pauwels EK, Bijvoet OL, Frijlink WB, Mulder JD, Hermans J.

*Radiology.* 1984 Dec;153(3):799-805.

**79. Some characteristics of local scintigraphic and radiologic patterns of Paget's disease of bone (osteitis deformans).**

Vellenga CJ, Pauwels EK, Bijvoet OL.

*Diagn Imaging Clin Med.* 1985;54(5):273-81.

**80. Hyperphosphataemia in hypophosphatasia**

Macfarlane JD, Harinck HI, Bijvoet OL.

*Neth J Med.* 1985;28(12):541-2.

**81. Influence of treatment with APD-bisphosphonate on the bone lesions in the mouse 512 multiple myeloma.**

Radl J, Croese JW, Zurcher C, van den Enden-Vieveen MH, Brondijk RJ, Kazil M, Haaijman JJ, Reitsma PH, Bijvoet OL.

*Cancer.* 1985 Mar 1;55(5):1030-40.

**82. Radiological demonstration of healing in Paget's disease of bone treated with APD.**

Vellenga CJ, Mulder JD, Bijvoet OL.

*Br J Radiol.* 1985 Sep;58(693):831-7.

**83. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis.**

Hoekman K, Papapoulos SE, Peters AC, Bijvoet OL.

*J Clin Endocrinol Metab* 1985 Nov;61(5):952-6.

**84. Magnetic resonance imaging in Paget's disease of the skull.**

Tjon-A-Tham RT, Bloem JU, Falke TH, Bijvoet OL, Gohel VK, Harinck BI, Ziedses des Plantes GB Jr.

*AJNR Am J Neuroradiol.* 1985 Nov-Dec;6(6):879-81.

**85. Quantitative bone scintigraphy in Paget's disease treated with APD.**

Vellenga CJ, Pauwels EK, Bijvoet OL, Harinck HI, Frijlink

*Br J Radiol.* 1985 Dec;58(696):1165-72.

**86. Bisphosphonates can reduce osteoclastic bone resorption by two different mechanisms.**

Löwik CW, Boonekamp PM, van de Pluym G, van de Wee-Pals L, Bloys van Treslong-de Groot H, Bijvoet OL.

*Adv Exp Med Biol.* 1986;208:275-81.

**87. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix**

Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL

*Bone Miner.* 1986 Feb;1(1):27-39.

**88. Effects of decreasing serum calcium on circulating parathyroid hormone and vitamin D metabolites in normocalcaemic and hypercalcaemic patients treated with APD.**

Papapoulos SE, Harinck HI, Bijvoet OL, Gleed JH, Fraher LJ, O'Riordan JL.

*Bone Miner.* 1986 Feb;1(1):69-78.

**89. Relation between signs and symptoms in Paget's disease of bone.**

Harinck HI, Bijvoet OL, Vellenga CJ, Blanksma HJ, Frijlink WB.

*Q J Med.* 1986 Feb;58(226):133-51.

**90. Consensus conference on osteoporosis.**

Bijvoet OL.

*Ned Tijdschr Geneesk.* 1986 Mar 29;130(13):584-90. Dutch.

**91. Osteolytic bone metastases in breast carcinoma pathogenesis, morbidity and bisphosphonate treatment.**

Elte JW, Bijvoet OL, Cleton FJ, van Oosterom AT, Sleeboom HP.

*Eur J Cancer Clin Oncol.* 1986 Apr;22(4):493-500. Review.

**92. Milk-alkali syndrome.**

Smit MJ, Bijvoet OL.

*Ned Tijdschr Geneeskd.* 1986 Apr 12;130(15):665-7. Dutch.

**93. Excessive crystal agglomeration with low citrate excretion in recurrent stone-formers.**

Kok DJ, Papapoulos SE, Bijvoet OL.

*Lancet.* 1986 May 10;1(8489):1056-8.

**94. Polysaccharide from coccoliths (CaCO<sub>3</sub> biomineral). Influence on crystallization of calcium oxalate**

Kok DJ, Blomen LJ, Westbroek P, Bijvoet OL

*Eur J Biochem.* 1986 Jul 1;158(1):167-72.

**95. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene**

Body JJ, Borkowski A, Cleeren A, Bijvoet OL.

*J Clin Oncol.* 1986 Aug;4(8):1177-83.

**96. Low inhibition of crystal agglomeration and citrate excretion in recurrent calcium oxalate stone formers.**

Kok DJ, Papapoulos SE, Bijvoet OL.

*Contrib Nephrol.* 1987;58:73-7.

**97. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.**

Boonekamp PM, Löwik OW, van der Wee-Pals LJ, van Wijk-van Lennep ML, Bijvoet OL

*Bone Miner.* 1987 Feb;2(1):29-42.

**98. A tumour-like bone lesion as a manifestation of Vitamin D-resistant hypophosphataemic osteomalacia.**

Papapoulos SE, Steendijk R, Bijvoet OL

*Br J Radiol.* 1987 Mar;60(711):285-6. A

**99. Efficacious management with aminobisphosphonate (APD) in Paget's disease of bone.**

Harinck HI, Bijvoet OL, Blanksma HJ, Dahlinghaus-Nienhuys PJ.

*Clin Orthop Relat Res.* 1987 Apr;(217):79-98.

**100. Ectopic production of 1.25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia.**

Mudde AH, van den Berg H, Boshuis PG, Breedveld FC, Markusse HM, Kluin PM, Bijvoet OL, Papapoulos SE.

*Cancer.* 1987 May 159(9):1543-6.

**101. Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride.**

Harinck HI, Bijvoet OL, Plantingh AS, Body JJ, Elte JW, Sleeboom HP, Wildiers J, Neljt JP.

*Am J Med.* 1987 Jun;82(6):1133-42

**102. Serum osteocalcin in Paget's disease of bone: basal concentrations and response to bisphosphonate treatment.**

Papapoulos SE, Frolich M, Mudde AH, Harinck HI, vd Berg H, Bijvoet OL.

*J Clin Endocrinol Metab.* 1987 Jul;65(1):89-94.

**103. Stimulation of bone resorption by inflamed nasal mucosa, dermonecrotic toxin-containing conditioned medium from *Pasteurella multocida*. and purified dermonecrotic toxin from *P. multocida*.**

Kimman TG, Löwik CW, van de Wee-Pals LJ, Thesingh OW, Defize P, Kamp EM, Bijvoet OL.

*Infect Immun.* 1987 Sep;55(9):2110-6.

**104. Paget's disease: a kind of chronic inflammation of the bone**

Bijvoet OL.

*Ned Tijdschr Geneeskd.* 1987 Sep 26;131(39):1705-10. Review. Dutch.

**105. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment**

van Holten-Verzantvoort AT, Bijvoet OL, Cleton FJ, Hermans J, Kroon HM, Harinck HI, Vermeij P, Elte JW, Neijjt JP, Beex UV, et al.

*Lancet.* 1987 Oct 31;2(8566):983-5.

**106. Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)**

Harinck HI, Papapoulos SE, Blanksma HJ, Moolenaar AJ, Vermeij P, Bijvoet OL.

*Br Med J (Clin Res Ed).* 1987 Nov 21;295(6609):1301-5.

**107. Bone scintigraphy and radiology in Paget's disease of bone: a review.**



Vellenga CJ, Bijvoet OL, Pauwels EK.  
*Am J Physiol Imaging*. 1988;3(3):154-68. Review.

**108. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.**

Löwik CW, van der Pluijm G, van der Wee-Pals LJ, van Treslong-De Groot HB, Bijvoet OL  
*J Bone Miner Res*. 1988 Apr;3(2):185-92.

**109. Modulation of calcium oxalate monohydrate crystallization kinetics in vitro.**

Kok DJ, Papapoulos SE, Blomen LJ, Bijvoet OL.  
*Kidney Int*. 1988 Sep;34(3):346-50.

**110. Effect of long-term bisphosphonate treatment on morbidity due to bone metastases in breast cancer.**

Cleton FJ, van Holten-Verzantvoort AT, Bijvoet OL.  
*Recent Results Cancer Res*, 1989;116:73-8.

**111. Precision of dual photon absorptiometry measurements: comparison of three different methods of selection of the region of interest.**

Valkema R, van den Berg R, Camps JA, Blokland JA, Papapoulos SE, Bijvoet OL, Pauwels EK.  
*Eur J Nucl Med*. 1989;15(4):183-8.

**112. The reproducibility of single photon absorptiometry in a clinical setting.**

Valkema R, Blokland JA, Papapoulos SE, Bijvoet OL, Pauwels EK,  
*Eur J Nucl Med*. 1989;15(5):269-73.

**113. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD.**

Valkema R, Vismans FJ, Papapoulos SE, Pauwels EK, Bijvoet OL.  
*Bone Miner*. 1989 Jan;5(2):183-92.

**114. Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis.**

Löwik CW, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OL, Aarden LA, Papapoulos SE.  
*Biochem Biophys Res Commun*. 1989 Aug 15;162(3):1546-52.

**115. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate.**

Papapoulos SE, Hoekman K, Löwik OW, Vermeij P, Bijvoet OL.  
*J Bone Miner Res*. 1989 Oct;4(5):775-81.

**116. A pharmacological background for the use of APD in cancer.**

Bijvoet OLM.  
*Disodium pamidronate (APD) in the treatment of malignancy-related disorders*. (Peter Burckhardt Ed). Hans Huber Publishers, Bern; 1989: 36-43.

**117. Crystal agglomeration is a major element in calcium oxalate urinary stone formation.**

Kok DJ, Papapoulos SE, Bijvoet OL.  
*Kidney Int*. 1990 Jan;37(1):51-6.

**118. Modulation of the production of a parathyroid hormone-like protein in human squamous carcinoma cell lines by interaction with fibroblasts.**

Hoekman K, Löwik CW, vd Ruit M, Kempenaar J, Bijvoet OL, Ponc M.  
*Cancer Res*. 1990 Jun 15;50(12):3589-94.

**119. Limited precision of lumbar spine dual-photon absorptiometry by variations in the soft-tissue background.**

Valkema R, Verheij LF, Blokland JA, Zwinderman AH, Bijvoet OL, Papapoulos SE, Pauwels EK.  
*Nucl Med*. 1990 Nov;31(11):1774-81.

**120. The effect of supportive pamidronate treatment on aspects of quality of life of patients with advanced breast cancer.**

van Holten-Verzantvoort AT, Zwinderman AH, Aaronson NK, Hermans J, van Emmerik B, van Dam FS, van den Bos B, Bijvoet OL, Cleton FJ.  
*Eur J Cancer*. 1991;27(5):544-9.

**121. Automatic region of interest determination in dual photon absorptiometry of the lumbar spine.**

Verheij LF, Blokland JK, Vossepoel AM, Valkema R, Camps JJ, Papapoulos SE, Bijvoet OM, Pauwels EJ.  
*Trans Med Imaging*. 1991;10(2):200-6.

**122. Automated comparison of dual-photon absorptiometric studies of the lumbar spine.**

Verheij LF, Blokland JA, Papapoulos SE, Bijvoet OL, Pauwels EK.  
*J Bone Miner Res.* 1991 Jun;6(6):575-81.

**123. Regulation of the production of plasminogen activators by bone resorption enhancing and inhibiting factors in three types of osteoblast-like cells.**

Hoekman K, Löwik CW, vd Ruit M, Bijvoet OL, Verheijen JH, Papapoulos SE.  
*Bone Miner.* 1991 Sep;14(3):189-204.

**124. Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants.**

van der Pluijm G, Löwik CW, de Groot H, Alblas MJ, van der Wee-Pals LJ, Bijvoet OL, Papapoulos SE.  
*J Bone Miner Res.* 1991 Nov;6(11):1203-10.

**125. The use of bisphosphonates in the treatment of osteoporosis.**

Papapoulos SE, Landman JO, Bijvoet OL, Löwik CW, Valkema R, Pauwels EK, Vermeij P.  
*Bone.* 1992;13 Suppl 1:S41-9. Review.

**126. The effect of tissue plasminogen activator (tPA) on osteoclastic resorption in embryonic mouse long bone explants: a possible role for the growth factor domain of tPA**

Hoekman K, Löwik CW, van de Ruit M, Bijvoet OL, Verheljen JH, Papapoulos SE.  
*Bone Miner.* 1992 Apr;17(1):1-13.

**127. Bisphosphonates in osteoporosis?**

Bijvoet OL, Valkema R, Löwik CW, Papapoulos SE.  
*Osteoporos Int.* 1993;3 Suppl 1:230-6. Review.

**128. Improved treatment of Paget's disease with dimethylamino-hydroxypropylidene bisphosphonate.**

Schweitzer DH, Zwinderman AH, Vermeil P, Bijvoet OL, Papapoulos SE.  
*J Bone Miner Res.* 1993 Feb;8(2):175-82.

**129. Palliative pamidronate treatment in patients with bone metastases from breast cancer.**

van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, Cleton FJ, Beex LV, Blijham G, Hermans J, Neijt JP, Papapoulos SE, Sleeboom HP, et al.  
*J Clin Oncol.* 1993 Mar;11(3):491-8.

**130. Dual photon absorptiometry for bone mineral measurements using a gamma camera.**

Valkema R, Prpic H, Blokland JA, Camps JA, Papapoulos SE, Bijvoet OL, Pauwels EK.  
*Acta Radiol.* 1994 Jan;35(1):45-52.

**131. Bisphosphonate on Bones.**

Bijvoet OL, Fleisch HA, Canfield RE, Russell RG (Eds).  
© 1995 Elsevier Science, BV.

**132. A lifetime of bisphosphonate.**

Bijvoet OL.  
*Medicina (B Aires).* 1997;57 Suppl 1:5-9.

**133. Horen en Zien**

Prof dr O.L.M. Bijvoet  
*Farewell, Leiden University (28 september 1993). Dutch.*

**134. Rickets before the discovery of vitamin D.**

Jeffrey LH O'Riordan and Olav LM Bijvoet  
*BoneKEy Reports* 3, Article number: 478 (2014) | doi:10.1038/bonekey.2013.212